LONDON - Proteome Sciences plc reported progress in its services business and continued recovery in TMT and reagent sales during the first half of the year at its Annual General Meeting held today.
Chairman Christopher Pearce stated that order levels in the company’s services business are advancing. The recovery in TMT and reagent sales follows cuts in U.S. National Institutes of Health budgets and academic grants in 2025, according to a press release statement.
Pearce said the company has made significant investment in the business over the past two years. He stated the company believes it is positioned to deliver returns from its activities in the proteomics field.
The company provides contract proteomics services for drug discovery, development and biomarker identification. Proteome Sciences employs proprietary workflows for analyzing tissues, cells and body fluids.
